Publications

2026

• Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development

  Hahn SM, Sharpless MD, Svedman C, et al. “Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development.” Journal of Clinical Oncology. 2026.

• Demographics, genomic testing, and JAK-inhibitor utilization in a novel, U.S. community oncology prospective registry for essential thrombocythemia and myelofibrosis

  Campos L, Svedman C, Guerra L, et al. “Demographics, genomic testing, and JAK-inhibitor utilization in a novel, U.S. community oncology prospective registry for essential thrombocythemia and myelofibrosis.” Clinical Cancer Research. 2026;32(14 Suppl):A058. AACR D3 abstract, published July 21, 2026.

• An AI-powered, human-in-the-loop, real-time registry platform to enable clinical trials, pragmatic studies, and prospective external control arms (ProECA) at scale in US community practices

  Campos LT, Guerra L, Fontaine A, et al. “An AI-powered, human-in-the-loop, real-time registry platform to enable clinical trials, pragmatic studies, and prospective external control arms (ProECA) at scale in US community practices.” Journal of Clinical Oncology. 2026;44(16_suppl):11058.

• 132 Characteristics and Treatments of Patients Receiving Two or More Lines of Treatment for Metastatic Triple-Negative Breast Cancer in the US Community Health Setting

  Stwalley B, Heim K, et al. “132 Characteristics and Treatments of Patients Receiving Two or More Lines of Treatment for Metastatic Triple-Negative Breast Cancer in the US Community Health Setting.” Oncology. 2026;40(4):144–145. 43rd Annual Miami Breast Cancer Conference Abstracts Supplement, May 5, 2026.

• Real-world treatment patterns and clinical outcomes among US patients with non-muscle invasive bladder cancer during the BCG shortage

  Merrill SB, et al. “Real-world treatment patterns and clinical outcomes among US patients with non-muscle invasive bladder cancer during the BCG shortage.” Journal of Clinical Oncology. 2026;44(16_suppl):4612.

2025

• Kaleido registry: A multi-center registry platform with site staff and automation to enable accelerated clinical research and drug development at scale in community practices

  Campos LT, Peguero JA, Guerra L, et al., including Svedman C. “Kaleido registry: A multi-center registry platform with site staff and automation to enable accelerated clinical research and drug development at scale in community practices.” Journal of Clinical Oncology. 2025;43(16_suppl):11020. ASCO abstract.

• Analysis of a pre-screening platform for clinical trials in patients with prostate cancer

  Avitia JW, Tucker V, Chung W-Y, et al., including Svedman C. “Analysis of a pre-screening platform for clinical trials in patients with prostate cancer.” Journal of Clinical Oncology. 2025;43(16_suppl):e17103. ASCO abstract.

• Genomic testing in newly diagnosed patients with metastatic non-small cell lung cancer: A report from a single centre within the Kaleido registry

  Peguero JA, Guerra L, Svedman C, et al. “Genomic testing in newly diagnosed patients with metastatic non-small cell lung cancer: A report from a single centre within the Kaleido registry.” Journal of Clinical Oncology. 2025;43(16_suppl):e13554. ASCO abstract.

• CO161 Developing and Evaluating Definitions of Real-World Clinical Endpoints for Patients with Early-Stage Triple-Negative Breast Cancer Using a US Secondary Database

  Hu X, Haiderali A, Rao Earla J, Cruz GI, Mohammed H, Privette T, Broome R, Hernandez A, Krishnan R, Pan W. “CO161 Developing and Evaluating Definitions of Real-World Clinical Endpoints for Patients with Early-Stage Triple-Negative Breast Cancer Using a US Secondary Database.” Value in Health. 2025;28(6 Suppl 1):S52–S53. Presented at ISPOR 2025, Montréal, May 13–16, 2025.

• HSR25-178 Initial Clinical Presentation and Pre-Diagnostic Journey During 18 Months Before a First Non-Small Cell Lung Cancer Diagnosis: US Retrospective Cohort Study

  Santorelli ML, Scannell Bryan M, Arunachalam A, Hu X, McBratney AE, Sweetnam C, Boice L, Wilkinson K, Broome RG, Berry AB, Izano MA. “HSR25-178 Initial Clinical Presentation and Pre-Diagnostic Journey During 18 Months Before a First Non-Small Cell Lung Cancer Diagnosis: US Retrospective Cohort Study.” Journal of the National Comprehensive Cancer Network. 2025;23(3.5):HSR25-178. Presented at the NCCN 2025 Annual Conference, Orlando, March 28–30, 2025.

• Peri-operative Treatment Patterns in Real-World Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Era of Adjuvant Immunotherapy

  Squires P, Meng K, Hu X, Turzhitsky V, Kao Y-H, Wermers Z, Stuart J, Ramamurthy C, Sweetnam C, Li H, Mamtani R. “Peri-operative Treatment Patterns in Real-World Muscle-Invasive Bladder Cancer Patients Undergoing Radical Cystectomy in the Era of Adjuvant Immunotherapy.” Journal of Clinical Oncology. 2025;43(5_suppl):704. Presented at the ASCO Genitourinary Cancers Symposium, San Francisco, February 13–15, 2025.